(Q51189605)

1 April 2018

title

Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. (English)

1 reference

1 April 2018

author

Sabina Antonela Antoniu

series ordinal

1

1 reference

1 April 2018

language of work or name

English

0 references

publication date

27 July 2012

1 reference

1 April 2018

Expert Opinion on Investigational Drugs

published in

1 reference

1 April 2018

volume

21

1 reference

1 April 2018

issue

11

1 reference

1 April 2018

page(s)

1607-1618

1 reference

1 April 2018

Signalling through phosphoinositide 3-kinases: the lipids take centre stage

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

MN-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 - 2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.712112

10.1517/13543784.2012.712112

21 January 2018

Identifiers

DOI

1 reference

1 April 2018

1 reference

1 April 2018